From: www.ecancer.tv on Fri, Jun 25 2010 11:59 AM

Jan Geissler discusses the role of patient advocacy groups and the efforts being made to help improve the spread and accessibility of information for patients.

From: www.ecancer.tv on Fri, Jun 25 2010 11:59 AM

Prof Hedy Kindler outlines the results of a randomised phase II trial investigating the use of conatumumab or AMG 479 as a treatment for pancreatic cancer. Both monoclonal antibodies had positive effects and led to an increased length of progression free survival, however this increase was great...

From: www.ecancer.tv on Fri, Jun 11 2010 1:49 PM

Dr Fabrice André - Continuous ErbB2 suppression - what options do we have? - Treatment Beyond the Current Paradigm, New Outlooks in Breast Cancer

From: www.ecancer.tv on Fri, Jun 11 2010 1:49 PM

Satellite Symposium: Treatment Beyond the Current Paradigm, New Outlooks in Breast CancerOfficial EBCC-7 Sponsored Satellite Symposium

From: www.ecancer.tv on Fri, Jun 11 2010 1:48 PM

Dr Antonio Llombart Cussac - Dr Antonio Llombart Cussac - Treatment Beyond the Current Paradigm, New Outlooks in Breast Cancer

From: www.ecancer.tv on Fri, Jun 11 2010 12:47 PM

Dr Alison Jones - Treatment Beyond the Current Paradigm - New outlooks in Breast Cancer

From: www.ecancer.tv on Fri, Jun 11 2010 11:47 AM

Prof Gordon McVie discusses the advances presented at this years ASCO conference. These include: the development of Ipilimumab, an antibody against the molecules that suppress T-cells; the development of anti-BRAF agents for lung cancer patients with the BRAF mutation; the increase in progressio...

From: www.ecancer.tv on Fri, Jun 11 2010 11:46 AM

Prof Christopher Twelves, speaking at the 2010 ASCO conference: A Phase III randomised trial finds that a new chemotherapy agent, eribulin mesylate, extends median overall survival by 2.5 months among women with locally recurrent or metastatic breast cancer who had already been heavily treated w...

From: www.ecancer.tv on Fri, Jun 11 2010 11:46 AM

Prof Yung-Jue Bang, speaking at the 2010 ASCO conference: A study featured in an ASCO plenary session shows that the majority of patients with advanced adenocarcinoma of the lung with a specific re-arrangement of the ALK gene responded to treatment with the investigational drug crizotinib (PF-02...

From: www.ecancer.tv on Fri, Jun 11 2010 10:45 AM

Dr Steven O’Day, speaking at the 2010 ASCO conference: A Phase III trial featured in an ASCO plenary session finds that patients with advanced, previously treated melanoma who received the monoclonal antibody ipilimumab lived 34 percent longer than those who received the immune-stimulating gp100...

From: www.ecancer.tv on Fri, Jun 11 2010 10:45 AM

Prof Robert A. Burger, speaking at the 2010 ASCO conference: A Phase III trial featured in an ASCO plenary session finds that adding bevacizumab (Avastin) to initial chemotherapy treatment, and then using it as maintenance therapy, significantly slows disease progression in women with advanced e...

From: www.ecancer.tv on Tue, Jun 08 2010 7:35 AM

Prof Fred Hirsch speaks about the shift towards individualised medication within the treatment of lung cancer. He outlines the role of genetic mutations, the progress that has been made developing new biomarkers, and recent developments in the chemo-prevention of lung cancer.

From: www.ecancer.tv on Tue, Jun 08 2010 5:31 AM

Prof Julien Mazieres, speaking at the 2010 ELCC conference, discusses chemo circulating cells; the importance of these cells as a prognostic factor and the challenges faced and techniques used to isolate them.

From: www.ecancer.tv on Tue, Jun 08 2010 5:31 AM

Prof Jan van Meerbeeck, discuses his research into the use of monoclonal antibodies to treat mesothelioma, a disease generally seen in professionally exposed individuals. Professor van Meerbeeck speaks about the future of lung cancer treatment and predicts a greater emphasis on individualised an...

From: www.ecancer.tv on Mon, Jun 07 2010 1:11 PM

Prof Nico van Zandwijk, talking to ecancer.tv at the 2010 ELCC conference, discusses the dangers of asbestos related diseases and his research and clinical trials into treating these. Asbestos is commonly used without regulations in many parts of the world, especially South East Asia which may l...

From: www.ecancer.tv on Mon, Jun 07 2010 1:11 PM

Prof Paul van Houtte, speaking at the 2010 ELCC conference, discusses the use of targeted radiotherapy to treat lung cancer. Advances such as the use of stereotactic body radiation therapy (SBRT) have had significant effects on the outcome of treatments in stage one patients. Prof van Houtte als...

From: www.ecancer.tv on Mon, Jun 07 2010 1:11 PM

Prof Paul Bunn speaks at the 2010 ELCC conference about developments in lung cancer treatments. Prof Bunn discusses the importance of oestrogen receptors, the need for tumour biopsies in order to provide personalised treatment, developments in the identification of mutations and providing mutati...

From: www.ecancer.tv on Mon, Jun 07 2010 1:11 PM

Prof Peter Harper, speaking at the ELCC conference 2010, talks about research being carried out to address the problems associated with lung cancer treatment for patients over 65 and the importance of bone metastases in lung cancer. Prof Harper also discusses possibilities of new drugs and the c...

From: www.ecancer.tv on Tue, May 25 2010 8:09 AM

Professor Wicha, speaking at AACR 2010, talks about research looking at the micro-environment around cancer stem cells, specifically in breast cancer.

From: www.ecancer.tv on Tue, May 25 2010 8:09 AM

Dr Pass, talking at AACR 2010, discusses the latest developments in the detection and treatment of mesothelioma, specifically the use of novel biomarkers and the ongoing studies to try and detect the disease earlier.